• Explore /
  • Poster
  • / CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.

CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.

Abstract Poster

Authors

null

Funda Meric-Bernstam

University of Texas MD Anderson Cancer Center, Houston, TX

Funda Meric-Bernstam , Richard J. Lee , Bradley Curtis Carthon , Othon Iliopoulos , James Walter Mier , Manish R. Patel , Nizar M. Tannir , Taofeek Kunle Owonikoko , Naomi B. Haas , Martin Henner Voss , James J. Harding , Ramaprasad Srinivasan , Geoffrey Shapiro , Melinda L. Telli , Pamela N. Munster , Richard D. Carvajal , Yonchu Jenkins , Sam H. Whiting , Johanna C. Bendell , Todd Michael Bauer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT02071862

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 549)

DOI

10.1200/JCO.2019.37.7_suppl.549

Abstract #

549

Poster Bd #

D10

Abstract Disclosures

Similar Posters

First Author: Nizar M. Tannir

First Author: Nizar M. Tannir

First Author: Nizar M. Tannir

First Author: Hai-Qiang Mai